Sentences with phrase «regenerative medicine company»
Regenerative medicine is a field that focuses on regrowing or repairing damaged tissues and organs in the body. Full definition
A Chinese regenerative medicine company will provide financial support, according to the account.
sciencemag.org
SAN DIEGO, October 11, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.
SAN DIEGO and SAN FRANCISCO, December 22, 2014 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced that Dr. Paul Laikind, President and Chief Executive Officer, will present and participate in moderated panel discussions at the upcoming Biotech Showcase ™ taking place January 12 - 15, 2015 in San Francisco.
San Diego, California, October 29, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell - derived cell therapy, announced today that the Company was granted over 20 patents worldwide in 2013 thus far, three U.S. and twenty foreign.
San Diego, May 22, 2017 — ViaCyte, Inc., a privately - held leading regenerative medicine company, announced today that the U.S. Food and Drug Administration (FDA) has allowed the company's Investigational New Drug Application (IND) for the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a potential cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.
About ViaCyte ViaCyte is a privately - held regenerative medicine company developing novel cell replacement therapies as potential long - term diabetes treatments to reduce the risk of hypoglycemia and diabetes - related complications.
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today the publication of a paper out of the University of Calgary in conjunction with co-authors from Kyoto University and the University of North Carolina, which further validates the company's ongoing clinical research using dermal sheath cup (DSC) cells to reverse the effects of pattern baldness.
Perth - based regenerative medicine company Avita Medical says it will be able to focus more on its core ReCell technology after completing the sale of its respiratory business for $ 2.47 million.
• Fortuna Fix, a Canada - based regenerative medicine company, raised $ 25 million in Series B funding.
The two co-founded the lab's first spinoff laboratory in its 115 - year history in 2013, regenerative medicine company Novo Biosciences Inc..
The 2017 Annual Data Report details industry - specific statistics and trends from more than 850 leading cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide.
Understanding the current IP landscape for regenerative medicine companies — What entreprenuers, scientists, tech tranfers directors and investors need to know about protecting their IP — Identifying and overcoming licensing issues
VetStem Biopharma, the leading Veterinary Regenerative Medicine Company, has partnered with Dr Jamie Gaynor and Peak Performance Veterinary Group to offer a Regenerative Medicine Center of Excellence.
SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.
San Diego, California, October 6, 2014 — ViaCyte, Inc., a privately - held regenerative medicine company developing a stem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follows:
ViaCyte is a privately - held, clinical - stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.
ViaCyte is a privately held, clinical - stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.
SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.
Regenerative medicine company Avita Medical has raised $ 10 million from investors to support the commercialisation of its ReCell device, which is being trialled by a US government agency.
New York and San Diego, May 22, 2017 — ViaCyte, Inc., a privately - held leading regenerative medicine company, and JDRF, the leading global organization funding type 1 diabetes research, jointly announced today JDRF grant funding to support the development of the PEC - Direct ™ islet cell replacement therapy being developed for type 1 diabetes patients with severe life - threatening hypoglycemia unawareness and related risks.
RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting the skin and tendons.
«I think this is an extremely important — and solid — paper,» says stem cell researcher Robert Lanza, vice president of research and scientific development at Applied Cell Technology, a regenerative medicine company headquartered in Alameda, Calif., who did not take part in the study.
Cynata Therapeutics Limited is an Australian clinical - stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus ™ stem cell technology platform.
SAN DIEGO, November 4, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company, today announced two presentations at upcoming healthcare events.
Cell Habitats US - based, pre-clinical stage, regenerative medicine company, founded in 2005.
SAN DIEGO, October 4, 2017 — ViaCyte, Inc., a privately - held regenerative medicine company, today announced upcoming company presentations at the Cell and Gene Meeting on the Mesa and the BIO Investor Forum.
SAN DIEGO, April 12, 2018 — ViaCyte, Inc., a privately - held regenerative medicine company, today announced President and CEO, Paul Laikind, Ph.D., will present at Alliance for Regenerative Medicine's 6th Annual Cell & Gene Therapy Investor Day in New York.
SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.
SAN DIEGO, August 12, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced a presentation at Rejuvenation Biotechnology 2016 (RB2016).
SAN DIEGO, June 16, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a company presentation at the 13th Annual Meeting of the International Society for Stem Cell Research (ISSCR).
Cynata Therapeutics Ltd (ASX: CYP) is a relatively young stem cell and regenerative medicine company.
SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.
San Diego, May 22, 2017 — ViaCyte, Inc., a privately - held leading regenerative medicine company, announced today $ 10 million in financing to support operations.
San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product candidate.
SAN DIEGO, July 21, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company, today announced that the California Institute for Regenerative Medicine (CIRM) approved a grant of $ 3.9 million to support pre-clinical development of ViaCyte's PEC - Direct cell therapy product candidate which is being developed for a subset of type 1 diabetes patients.
SAN DIEGO and SAN FRANCISCO, February 23, 2017 — ViaCyte, Inc., a privately - held regenerative medicine company, and Beyond Type 1, a not - for - profit advocacy and education group for those living with type 1 diabetes, today announced a grant from Beyond Type 1 to support ViaCyte's efforts to develop a functional cure for type 1 and other insulin - requiring diabetes.
Novo Biosciences based of Bar Harbor, Maine is a regenerative medicine company developing small molecule therapies that reactivate and stimulate innate healing abilities in humans and animals.
San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.
Novo Biosciences is a regenerative medicine company that is developing small molecule therapies that reactivate and stimulate innate healing abilities in humans and animals.
SAN DIEGO, June 22, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced two presentations at ISSCR 2016 Annual Meeting.
San Diego, CA, May 29, 2014 — ViaCyte, Inc., a regenerative medicine company focused on developing a cell replacement therapy for the treatment of patients with insulin - dependent diabetes, announced today that the Company has settled a patent dispute involving certain of the Company's definitive endoderm patents and patent applications.
AxoGen, Inc. is a regenerative medicine company, which is focused on the science, development and commercialization of technologies for peripheral nerve solutions.
AxoGen Inc is a regenerative medicine company.